Monte Rosa officer granted options and RSUs

Monte Rosa Therapeutics, Inc. Principal Accounting Officer Matthew Bowen received new equity awards.

Rhea-AI Filing Summary

Monte Rosa Therapeutics, Inc. Principal Accounting Officer Matthew Bowen received new equity awards. He was granted a stock option covering 19,500 shares of common stock at an exercise price of $16.93 per share, expiring on April 5, 2036. Separately, he received 4,300 restricted stock units, each representing one share upon vesting. The RSUs vest 25% on April 6, 2027, with the remainder in three equal annual installments, while the option vests 25% on April 6, 2027 and then in 36 substantially equal monthly installments, in each case subject to continued service. Following the RSU grant, he directly owns 25,904 shares of common stock.

Insider Trade Summary

Grant/Award: 23,800 shares

Grant/Award 2 txns

Insider Bowen Matthew

Role Principal Accounting Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	19,500	$0.00	$0.00
Grant/Award	Common Stock	4,300	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 19,500 contracts (Direct); Common Stock — 25,904 shares (Direct)

Footnotes (2)

1. F1. Represents restricted stock units ("RSUs") granted under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 25% of the RSUs shall vest on April 6, 2027, with the remainder vesting in 3 equal annual installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
2. F2. 25% of this option shall vest and become exercisable on April 6, 2027, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Key Figures

Option grant size: 19,500 shares Option exercise price: $16.93 per share Option expiration: April 5, 2036 +3 more

6 metrics

Option grant size 19,500 shares Stock Option (Right to Buy) granted April 6, 2026

Option exercise price $16.93 per share Exercise price for 19,500-share option

Option expiration April 5, 2036 Expiration date of stock option grant

RSU grant size 4,300 units Restricted stock units granted April 6, 2026

Initial vesting date April 6, 2027 25% of RSUs and 25% of option vest on this date

Common shares after grant 25,904 shares Total common stock held directly after RSU acquisition

Key Terms

restricted stock units ("RSUs"), 2021 Stock Option and Incentive Plan, Stock Option (Right to Buy), vesting

4 terms

restricted stock units ("RSUs") financial

"Represents restricted stock units ("RSUs") granted under the Issuer's 2021 Stock Option and Incentive Plan."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

2021 Stock Option and Incentive Plan financial

"RSUs granted under the Issuer's 2021 Stock Option and Incentive Plan."

Stock Option (Right to Buy) financial

"security_title": "Stock Option (Right to Buy)""

vesting financial

"25% of the RSUs shall vest on April 6, 2027, with the remainder vesting in 3 equal annual installments thereafter"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did GLUE executive Matthew Bowen receive?

Matthew Bowen received a stock option for 19,500 shares and 4,300 restricted stock units. The option has a $16.93 exercise price, and both awards vest over multiple years, subject to his continued service with Monte Rosa Therapeutics.

How do the new stock options for GLUE’s Matthew Bowen vest?

The 19,500-share stock option vests 25% on April 6, 2027, with the remaining 75% vesting in 36 substantially equal monthly installments. Vesting is conditioned on Matthew Bowen’s continued service on each applicable vesting date.

What is the vesting schedule for Matthew Bowen’s GLUE RSU grant?

The 4,300 restricted stock units vest 25% on April 6, 2027, with the remaining 75% vesting in three equal annual installments thereafter. Each vested RSU settles into one share of Monte Rosa Therapeutics common stock, subject to continued service.

What is the exercise price and expiration date of GLUE’s new option grant?

The stock option granted to Matthew Bowen has an exercise price of $16.93 per share and an expiration date of April 5, 2036. It represents a right to buy Monte Rosa Therapeutics common stock once vested and exercised.

How many GLUE common shares does Matthew Bowen hold after these awards?

After the grant of 4,300 restricted stock units reported as common stock, Matthew Bowen directly holds 25,904 shares of Monte Rosa Therapeutics common stock. This figure reflects his position following the latest reported acquisition transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/07/2026 - 04:10 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bowen Matthew

(Last) (First) (Middle)

MONTE ROSA THERAPEUTICS, INC.

321 HARRISON AVENUE, SUITE 900

(Street)

BOSTON MASSACHUSETTS 02118

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Monte Rosa Therapeutics, Inc. [ GLUE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Principal Accounting Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/06/2026		A		4,300	A	(1)	25,904	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$16.93	04/06/2026		A		19,500		(2)	04/05/2036	Common Stock	19,500	$0	19,500	D

Explanation of Responses:

1. Represents restricted stock units ("RSUs") granted under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 25% of the RSUs shall vest on April 6, 2027, with the remainder vesting in 3 equal annual installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

2. 25% of this option shall vest and become exercisable on April 6, 2027, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

	/s/ Phil Nickson, Attorney-in-Fact	04/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)